New York State Teachers Retirement System decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 166,940 shares of the medical research company's stock after selling 9,518 shares during the period. New York State Teachers Retirement System owned about 0.09% of IQVIA worth $39,560,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of the company. Versant Capital Management Inc raised its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the second quarter valued at approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the third quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new position in IQVIA in the 2nd quarter valued at $29,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA during the 2nd quarter worth $32,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, insider Eric Sherbet sold 1,300 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company's stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Morgan Stanley increased their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday, July 23rd. Argus raised shares of IQVIA to a "strong-buy" rating in a research note on Wednesday, July 31st. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They issued a "buy" rating and a $276.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on IQVIA from $288.00 to $279.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 23rd. Finally, Robert W. Baird lifted their price target on IQVIA from $251.00 to $256.00 and gave the stock a "neutral" rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $267.27.
Read Our Latest Report on IQVIA
IQVIA Trading Down 4.7 %
NYSE:IQV traded down $10.22 during trading hours on Thursday, reaching $205.82. 3,250,079 shares of the stock were exchanged, compared to its average volume of 1,084,073. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The business has a 50-day moving average of $235.88 and a two-hundred day moving average of $230.06. The company has a market capitalization of $37.52 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 2.09 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
